KL.01 Ending the HIV/AIDS Pandemic: From Scientific Advances to Public Health Implementation
PL.01 Plenary Session 1
PL01.2 HPV: Changing Screening Algorithms and Scaling Up Vaccination
PL.02 Plenary Session 2
PL02.1 The Dynamic Evolution of Sexual Behavior as It Impacts STD Spread
PL02.2 Maximizing Impact and Return on Investments in STD/HIV Prevention Programmes
PL02.3 HIV Transmission Dynamics; Can We Translate Knowledge into Action
PL.03 Plenary Session 3: Anton Luger Memorial
PL03.1 STIs - 2013: Resurgence of Early Syphilis, Persistence of High STI Morbidity and Mortality, and Emergence of Antimicrobial Resistant STIs: Implications and Potential Responses
PL03.2 Control of syphilis in the world’s most populous country: opportunities and challenges
PL03.3 Syphilis: From Pathogenesis to Control
PL.04 Plenary Session 4
PL04.1 Sexual Behaviour and STIs in Men Who Have Sex with Men: A Global Perspective
PL04.2 Sex Hormones, HIV Infection and Unintended Pregnancy: Ever Since Adam and Eve
PL04.3 Protective and Non-Protective Immunity in STIs
PL.05 Plenary Session 5
PL05.1 PrEP & Treatment as Prevention for HIV: Finding the Balance
PL05.2 New Technologies in STI Diagnosis and Control: Promising Future
Debate 03: Adolescent and Neonatal Circumcision Should Be Promoted Globally for HIV Control
S.01 Microbicides To Prevent HIV/STD 2013: An Update
S01.1 An update on topical microbicide development
S01.2 Vaginal delivery of microbicides: Multipurpose Technologies.
S01.3 Making anal sex safe: current status of products for rectal use
S.02 Translating and Implementing the Results of Diagnostic Assay Evaluations: From the Research Laboratory to Patient Care
S02.2 Overview of Rapid/Point of Care Diagnostic Tests for HIV and Current Challenges associated with HIV Testing
S02.3 Extra-genital CT/GC Testing by NAATS: Use in screening and prevalence of infection in MSM, issues in validation
S02.4 What are the most efficient ways to communicate research derived information to clinical practice: the role of diagnostic and treatment guidelines, packet inserts, clinicians’ perspective
S.03 Advancing Prevention of Sexually Transmitted Infections through Sexual Health Promotion: Opportunities and Lessons Learned (organised by CDC/WHO/ECDC)
S03.1 Sexual health: conceptual framework and recommendations for indicators
S03.2 Sexual health promotion interventions: results of a systematic review
S03.3 Addressing gender-based violence to reduce risk of STI and HIV
S03.4 Sexual health in the European Union: an inventory of data, programmes, initiatives, and policies
S03.5 Advancing sexual health in the US: from theory to action
S.04 Scaling up of HIV treatment programs among the most at-risk populations in low- and middle-income countries
S04.1 Scaling up of HIV treatment programs among the most at-risk populations in low- and middle-income countries - introduction
S04.2 Modelling the impact of early anti-retroviral treatment amongst people who inject drugs in a high prevalence setting
S04.4 ART among FSW in South Africa
S04.5 ART among FSW in India
S.05 Fostering an Integrated Approach to the Control of Antimicrobial Resistance in Neisseria gonorrhoeae (WHO Symposium)
S05.3 Genetic resistance determinants for extended-spectrum cephalosporins - possibilities for genetic resistance testing?
S05.4 Integrating antimicrobial susceptibility monitoring in Neisseria gonorrhoeae to broader AMR agenda
S.06 How Does Your Partner Know?
S06.1 Treating contacts to gonorrhea and chlamydia without a clinic visit; the efficacy and effectiveness of different models
S06.2 Using social media for partners services in adolescents.
S06.3 MSM Partner Services: What works?
S06.4 New directions in HIV partner services: an evolving model of global, integrated field services
S.07 Bacterial Virulence and Host Response
S07.2 The extrusion paradigm of Chlamydia pathogenesis
S07.3 Survival Strategies of Haemophilus ducreyi: Role of Transporters
S07.4 Identification of determinants triggering antigenic variation in Mycoplasma genitalium
S07.5 Understanding dissemination of Treponema pallidum within the host - is there hope for a syphilis vaccine?
S.08 STI/HIV Treatment Guidelines: Important Areas of Clinical Uncertainty
S08.2 Is azithromycin the best treatment for chlamydia?
S08.3 Mycoplasma genitalium and Chlamydia trachomatis in laparoscopically diagnosed pelvic inflammatory disease
S08.4 Mycoplasma genitalium: implications for disease, treatment and the public health
S.09 Molecular Mechanisms of Antimicrobial Resistance
S09.1 Molecular detection of antimicrobial resistance in STI pathogens
S09.2 Neisseria gonorrhoeae: are we exerting the selective pressure?
S09.3 Herpes simplex virus
S09.4 Mycoplasma genitalium
S.10 HIV Treatment as Prevention
S10.1 Predicting the Social and Behavioural Consequences.
S10.2 Determining uptake, adherence, & patterns of ART use as prevention
S10.3 Modeling the effect of TAP on the HIV/AIDS Epidemic
S.11 National Trends in Sexual Behavior: USA, UK and Switzerland
S11.1 Sexual behaviour in Britain in the new millennium: A new era?
S11.2 Sex in the United States in the New Millennium: Temporal Trends among Men and Women Aged 15-44 Years
S11.3 Switzerland: national trends in sexual behaviour in the context of HIV/STI behavioural surveillance 1987-2012
S.12 STD Vaccines and Correlates of Immunity
S12.1 Human Papillomavirus Vaccines - Correlates of Protection are not defined
S12.3 Understanding how broadly cross-neutralizing antibodies develop in HIV infection - clues for HIV vaccine development?
S12.4 Chlamydia trachomatis.
S.13 Challenges to a Comprehensive Approach to the Prevention of HIV and STI among Men who have Sex with Men in Europe (organised by ECDC)
S13.1 Current and future challenges in gay men’s health
S13.2 Evidence-based targeted review of HIV and STI prevention interventions among MSM
S13.3 The status of HIV prevention among MSM: an overview of the European response
S.14 New strategies and implementation of best practices for dual elimination of mother-to-child transmission of syphilis and HIV (organised by WHO)
S14.2 The CISNE Project: Implementation of POCT for syphilis and HIV in antenatal care and reproductive health services in Peru
S14.3 Explaining inaction: the politics of congenital syphilis and the global health agenda
S14.4 Monitoring the finish-line: integrated global criteria and processes for validation of EMTCT of syphilis and HIV
S14.5 Piloting methods for validation of elimination of MTCT of HIV and syphilis in St. Lucia and Chile
S.15 Sexual Networks and Contagion (Insights from phylodynamic studies, behaviour diffusion, social media studies)
S15.1 Frequent viral introductions sustain local HIV epidemics in rural Africa
S15.2 Social networking and diffusion of risks and interventions among youth
S15.4 Discussant. Implications of Sexual Networks.
S.16 Challenging Clinical Conditions
S16.2 Recurrent BV
S16.3 Recurrent TV: The potential of molecular techniques to improve clinical practice
S16.4 Lymphogranuloma venereum in Men who have Sex with Men. An ongoing epidemic since 10 years, but still not tackled
S16.5 Management of syphilis in pregnancy
S.17 Scientific Tracks: Summary and Highlights
S17.1 Basic Science
S17.2 Clinical Science
S17.3 Epidemiology and Prevention Sciences
S17.4 Social and Behavioural Sciences
S17.5 Implementation Science
S17.6 Programme Science and Policy